Indicaton
Tucatinib is an investigational oral, potent, small molecule tyrosine kinase inhibitor that is highly selective for HER2 and is in a pivotal registration trial in HER2+ metastatic breast cancer.
Tucatinib is an investigational oral, potent, small molecule tyrosine kinase inhibitor that is highly selective for HER2 and is in a pivotal registration trial in HER2+ metastatic breast cancer.